What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?

Anders Wallin; Suvarna Alladi; Sandra E. Black; Christopher Chen; Steven M. Greenberg; Deborah Gustafson; Jeremy D. Isaacs; Hanna Jokinen; Raj Kalaria; Vincent Mok; Leonardo Pantoni; Florence Pasquier; Gustavo C. Roman; Gary A. Rosenberg; Reinhold Schmidt; Eric E. Smith; Atticus H. Hainsworth

doi:10.1016/j.cccb.2022.100044

What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?

Anders Wallin, Suvarna Alladi, Sandra E. Black, Christopher Chen, Steven M. Greenberg, Deborah Gustafson, Jeremy D. Isaacs, Hanna Jokinen, Raj Kalaria, Vincent Mok, Leonardo Pantoni, Florence Pasquier, Gustavo C. Roman, Gary A. Rosenberg, Reinhold Schmidt, Eric E. Smith, Atticus H. Hainsworth

Research output: Contribution to journal › Editorial › peer-review

9 Scopus citations

Abstract

•Controversial registration of aducanumab for Alzheimer's Disease•Aducanumab is the subject of post-licensing observational studies aiming to follow the effects of the drug•Given the high prevalence of cerebrovascular pathology it is important that these studies do not ignore vascular cognitive disorders•The studies may give detailed phenotyping data that may lead to knowledge of targets for treatments of patients with vascular cognitive disorders.

Original language	English (US)
Article number	100044
Pages (from-to)	100044
Journal	Cerebral Circulation - Cognition and Behavior
Volume	3
DOIs	https://doi.org/10.1016/j.cccb.2022.100044
State	Published - Jan 2022

ASJC Scopus subject areas

Behavioral Neuroscience
Cognitive Neuroscience
Biological Psychiatry
Neurology
Clinical Neurology

Access to Document

10.1016/j.cccb.2022.100044

Cite this

Wallin, A., Alladi, S., Black, S. E., Chen, C., Greenberg, S. M., Gustafson, D., Isaacs, J. D., Jokinen, H., Kalaria, R., Mok, V., Pantoni, L., Pasquier, F., Roman, G. C., Rosenberg, G. A., Schmidt, R., Smith, E. E., & Hainsworth, A. H. (2022). What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders? Cerebral Circulation - Cognition and Behavior, 3, 100044. Article 100044. https://doi.org/10.1016/j.cccb.2022.100044

Wallin, A, Alladi, S, Black, SE, Chen, C, Greenberg, SM, Gustafson, D, Isaacs, JD, Jokinen, H, Kalaria, R, Mok, V, Pantoni, L, Pasquier, F, Roman, GC, Rosenberg, GA, Schmidt, R, Smith, EE & Hainsworth, AH 2022, 'What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?', Cerebral Circulation - Cognition and Behavior, vol. 3, 100044, pp. 100044. https://doi.org/10.1016/j.cccb.2022.100044

@article{9cd9beb7c4454047bbc8db6020177f3d,

title = "What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?",

abstract = "•Controversial registration of aducanumab for Alzheimer's Disease•Aducanumab is the subject of post-licensing observational studies aiming to follow the effects of the drug•Given the high prevalence of cerebrovascular pathology it is important that these studies do not ignore vascular cognitive disorders•The studies may give detailed phenotyping data that may lead to knowledge of targets for treatments of patients with vascular cognitive disorders.",

author = "Anders Wallin and Suvarna Alladi and Black, {Sandra E.} and Christopher Chen and Greenberg, {Steven M.} and Deborah Gustafson and Isaacs, {Jeremy D.} and Hanna Jokinen and Raj Kalaria and Vincent Mok and Leonardo Pantoni and Florence Pasquier and Roman, {Gustavo C.} and Rosenberg, {Gary A.} and Reinhold Schmidt and Smith, {Eric E.} and Hainsworth, {Atticus H.}",

note = "{\textcopyright} 2022 Published by Elsevier B.V.",

year = "2022",

month = jan,

doi = "10.1016/j.cccb.2022.100044",

language = "English (US)",

volume = "3",

pages = "100044",

journal = "Cerebral Circulation - Cognition and Behavior",